OPEN END TURBO OPTIONSSCHEIN SHORT - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 10:26:11 2024-07-01 EDT | ||
| 4.32 EUR | -3.14% |
|
| 1 month | -35.27% | ||
| 3 months | -53.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 4.32 | -3.14% |
| 24-06-28 | 4.46 | -0.89% |
| 24-06-27 | 4.5 | -0.44% |
| 24-06-26 | 4.52 | -1.09% |
| 24-06-25 | 4.57 | +5.79% |
Real-time BOERSE MUENCHEN
Last update July 01, 2024 at 10:26 am
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG1YXB |
| ISIN | DE000GG1YXB3 |
| Date issued | 2024-01-08 |
| Strike | 521.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.42 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.19 € |
|---|---|
| Lowest since issue | 3.45 € |
| Spread | 0.1 € |
| Spread % | 2.16% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Certificates
- Certificat
